Drugs for Cutis Laxa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 40)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
2 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
3 |
|
Brimonidine Tartrate |
|
Phase 4 |
|
70359-46-5 |
|
Synonyms:
AGN-190342LF
AGN-190342-LF
ALPHAGAN
ALPHAGAN P
BRIMONIDINE D-TARTRATE
BRIMONIDINE TARTRATE
|
BRYMONT
LUMIFY
MIRVASO
QOLIANA
UK-1430418
|
|
4 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
5 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
6 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
7 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
8 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
9 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
10 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
11 |
|
Hemostatics |
|
Phase 4 |
|
|
|
12 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
13 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
14 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
15 |
|
Anesthetics |
|
Phase 4 |
|
|
|
16 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
17 |
|
Carotenoids |
|
Phase 3 |
|
|
|
18 |
|
Droxidopa |
Approved, Investigational |
Phase 1, Phase 2 |
|
23651-95-8 |
443940 92974 |
Synonyms:
(-)-(2S,3R)-2-AMINO-3-HYDROXY-3-(3,4-DIHYDROXYPHENYL)PROPANOIC ACID
(2R,3S)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate
(2S,3R)-3,4-DIHYDROXY-PHENYLSERINE
3,4 Dihydroxyphenylserine
3,4 Threo dops
3,4-Dihydroxyphenylserine
3,4-Threo-dops
DL Threo 3,4 dihydroxyphenylserine
DL-Threo-3,4-dihydroxyphenylserine
Dops
Droxidopa
Droxidopa, (DL-tyr)-isomer
Droxydopa
Erythro 3,4 dihydroxyphenylserine
|
Erythro-3,4-dihydroxyphenylserine
L-Dihydroxyphenylserine
L-DOPS
L-DOPS|Northera®|SM-5688
L-Threo-3,4-dihydroxyphenylserine
L-threo-dihydroxyphenylserine
L-THREODOPS
Northera
SM 5688
SM-5688
Threo dops
THREO-DOPASERINE
Threo-dops
|
|
19 |
|
Antiparkinson Agents |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Hormones |
|
Phase 1 |
|
|
|
21 |
|
Calcium, Dietary |
|
Phase 1 |
|
|
|
22 |
|
Calcium |
Nutraceutical |
Phase 1 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
23 |
|
Ibuprofen |
Approved |
|
|
15687-27-1 |
3672 |
Synonyms:
(+-)-2-(p-Isobutylphenyl)propionate
(+-)-2-(p-Isobutylphenyl)propionic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-Ibuprofen
(+-)-p-Isobutylhydratropate
(+-)-p-Isobutylhydratropic acid
(+-)-Α-methyl-4-(2-methylpropyl)benzeneacetate
(+-)-Α-methyl-4-(2-methylpropyl)benzeneacetic acid
(±)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
(±)-IBUPROFEN
(±)-P-ISOBUTYLHYDRATROPIC ACID
(±)-Α-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
(4-Isobutylphenyl)-alpha-methylacetate
(4-Isobutylphenyl)-alpha-methylacetic acid
(4-Isobutylphenyl)-a-methylacetate
(4-Isobutylphenyl)-a-methylacetic acid
(4-Isobutylphenyl)-α-methylacetate
(4-Isobutylphenyl)-α-methylacetic acid
(RS)-Ibuprofen
2-(4-Isobutylphenyl)propanoate
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropate
4-Isobutylhydratropic acid
a-(4-Isobutylphenyl)propionate
a-(4-Isobutylphenyl)propionic acid
a-(p-Isobutylphenyl)propionate
a-(p-Isobutylphenyl)propionic acid
ACHES-N-PAIN
Actiprofen
Adran
Advil
ADVIL LIQUI-GELS
ADVIL MIGRAINE LIQUI-GELS
Advil®|Brufen®|ibuprofen lysine|ibuprofen sodium|Motrin®|Nurofen®|U-18573
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(p-Isobutylphenyl)propionate
alpha-(p-Isobutylphenyl)propionic acid
alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
alpha-p-Isobutylphenylpropionate
alpha-p-Isobutylphenylpropionic acid
Aluminum salt ibuprofen
Amersol
Amibufen
ANADIN JOINT PAIN
ANADIN LIQUIFAST
ANADIN PERIOD PAIN RELIEF
ANADIN ULTRA
Anco
Andran
Anflagen
Apo-Ibuprofen
Apsifen
APSIFEN-F
ARTHROFEN 200
ARTHROFEN 400
ARTHROFEN 600
Artril 300
Bluton
Brufanic
Brufen
BRUFEN RET
Brufort
Buburone
Butylenin
Calcium salt ibuprofen
CALDOLOR
CAP-PROFEN
CHILDREN'S ADVIL
CHILDREN'S ADVIL-FLAVORED
CHILDREN'S ELIXSURE
CHILDREN'S IBUPROFEN
CHILDREN'S MOTRIN
CODAFEN CONTINUS
Codral
CO-OP
CUPROFEN FOR CHILD
CUPROFEN PLUS
DEEP RELIEF
Dolgin
Dolgirid
Dolgit
Dolocyl
Dolo-dolgit
Duralbuprofen
Ebufac
Emodin
Epobron
Femadon
FEMAFEN
FENBID
FENBID FTE
Fenbid Spansule
FENPAED
FEVERFEN
FLEXIMEX
Haltran
I.V. solution, ibuprofen
IB-100
Ibu
Ibu-attritin
IBUCALM
IBUDERM
IBUFAC
Ibufen
IBUGEL
IBUGEL FTE
IBULAR
IBULEVE
IBUMED
Ibumetin
IBUMOUSSE
IBUPRIN
Ibuprocin
IBUPROFEN
Ibuprofen i.v. solution
Ibuprofen zinc
|
Ibuprofen, (+-)-isomer
Ibuprofen, (R)-isomer
Ibuprofen, (S)-isomer
Ibuprofen, aluminum salt
Ibuprofen, calcium salt
Ibuprofen, copper (2+) salt
Ibuprofen, magnesium salt
Ibuprofen, potassium salt
Ibuprofen, sodium salt
Ibuprofen, zinc salt
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprofen-zinc
IBUPROHM
IBUPROPHEN
IBU-SLO
IBUSPRAY
IBU-TAB
IBU-TAB 200
Ibutid
IBUTIME
Ifen
Inabrin
Inoven
IP 82
IP-82
ISISFEN
JUNIFEN
JUNIOR STRENGTH ADVIL
JUNIOR STRENGTH IBUPROFEN
JUNIOR STRENGTH MOTRIN
Lamidon
Lebrufen
LIDIFEN
LIDIFEN-F
Liptan
LOBUFEN
M01AE01
Magnesium salt ibuprofen
MANDAFEN
MANORFEN
MAXA-GESIC
Medipren
MIDOL
Midol 200
MIDOL LIQUID GELS
MIGRAFEN
Motrin
MOTRIN IB
MOTRIN MIGRAINE PAIN
Mynosedin
Napacetin
NeoProfen
Nobfelon
Nobfen
Nobgen
NOVAPRIN
Novogent N
Novoprofen
NSC-256857
Nuprin
Nurofen
NUROFEN 400
NUROFEN BACK PAIN SR
NUROFEN CHILD
NUROFEN FOR CHILD
NUROFEN PLUS
NUROFEN RECOVERY
NUROFEN SINUS
NUROFEN SOLB
ORBIFEN
PACIFENE
Pantrop
Para-Isobutylhydratropic Acid
PAXOFEN
PEDEA
Pediaprofen
Pedia-Profen
PEDIATRIC ADVIL
PHENSIC
PHOR PAIN
PHORPAIN
PHORPAIN MAX STRGH
p-Isobutyl-2-phenylpropionate
p-Isobutyl-2-phenylpropionic acid
p-Isobutylhydratropate
p-Isobutylhydratropic acid
Potassium salt ibuprofen
PROFEN
PROFLEX
PROFLEX SR
Rafen
RD 13621
Rebugen
RELCOFEN
RIMAFEN
Roidenin
Rufen
Salprofen
Salt ibuprofen, magnesium
Salt ibuprofen, sodium
Salt ibuprofen, zinc
Seclodin
Sodium salt ibuprofen
Suspren
Tabalon
TAB-PROFEN
Trauma dolgit gel
Trauma-dolgit gel
TraumaDolgit gel
Trendar
U-18573
Urem
Zinc salt ibuprofen
Α-(4-isobutylphenyl)propionate
Α-(4-isobutylphenyl)propionic acid
Α-(p-isobutylphenyl)propionate
Α-(p-isobutylphenyl)propionic acid
|
|
24 |
|
Bimatoprost |
Approved, Investigational |
Early Phase 1 |
|
155206-00-1 |
5311027 |
Synonyms:
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
AGN 192024
AGN 192024|LS-181817|Lumigan®
AGN-192024
BIMATOPROST
|
Bimatoprostum
Latisse
LS-181817
Lumigan
|
|
25 |
|
Hyaluronic acid |
Approved, Vet_approved |
|
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
26 |
|
Sorbitol |
Approved, Investigational |
|
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
27 |
|
Kava |
Approved, Investigational, Nutraceutical |
|
|
9000-38-8 |
|
28 |
|
Dermatologic Agents |
|
|
|
|
|
29 |
|
Radiation-Protective Agents |
|
|
|
|
|
30 |
|
Deuterium Oxide |
|
|
|
|
|
31 |
|
Protective Agents |
|
|
|
|
|
32 |
|
Adjuvants, Immunologic |
|
|
|
|
|
33 |
|
Viscosupplements |
|
|
|
|
|
34 |
|
incobotulinumtoxinA |
|
|
|
|
|
Synonyms:
|
35 |
|
Immunologic Factors |
|
|
|
|
|
36 |
|
Analgesics |
|
|
|
|
|
37 |
|
Acetaminophen, hydrocodone drug combination |
|
|
|
|
|
38 |
|
Pharmaceutical Solutions |
|
|
|
|
|
39 |
|
Ophthalmic Solutions |
|
Early Phase 1 |
|
|
|
40 |
|
diuretics |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 82)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Vibration-Assisted Anaesthesia: A Randomised Controlled Trial to Investigate Whether Vibration Reduces the Pain of Anaesthetic Injection in Eyelid Surgery |
Completed |
NCT00793988 |
Phase 4 |
|
2 |
Suture Granuloma in Body Contouring Surgery |
Completed |
NCT00223132 |
Phase 4 |
|
3 |
Efficacy of Intraoperative Brimonidine for Hemostasis During Eyelid Surgery |
Recruiting |
NCT05480098 |
Phase 4 |
Brimonidine Topical |
4 |
A Prospective Study Evaluating the Effectiveness of Juvederm Volift With Lidocaine for Treatment of the Aging Hands |
Active, not recruiting |
NCT04390581 |
Phase 4 |
|
5 |
The Derm Aid Study |
Completed |
NCT04249128 |
Phase 3 |
|
6 |
Safety and Efficacy of Sofwave Treatment to Lift Lax Skin |
Completed |
NCT04829227 |
Phase 3 |
|
7 |
Safety and Efficacy of Sofacia Treatment to Improve Facial Lines and Wrinkles, to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow |
Recruiting |
NCT04969380 |
Phase 3 |
|
8 |
Evaluation the Safety and Efficacy of the Treatment of Scars and Cutis Laxa Syndrome With the Use of Autologous (Fresh and Stored) Stem Cells Isolated From Adipose Tissue. |
Completed |
NCT03887208 |
Phase 1, Phase 2 |
|
9 |
Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow |
Completed |
NCT04146584 |
Phase 2 |
|
10 |
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial |
Recruiting |
NCT04977388 |
Phase 1, Phase 2 |
Droxidopa |
11 |
Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity |
Active, not recruiting |
NCT04176068 |
Phase 1 |
|
12 |
Thermage FLX System to Treat the Face, Neck, and Eyelids for Correction of Mild to Moderate Skin Laxity. |
Unknown status |
NCT03894371 |
|
|
13 |
Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery |
Unknown status |
NCT04235803 |
|
|
14 |
Combination Therapy for Rejuvenation of the Lower Face and Neck |
Unknown status |
NCT04102670 |
|
|
15 |
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring With an Optimized Post-Procedure Treatment Plan |
Unknown status |
NCT03853980 |
|
|
16 |
A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of a Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles |
Unknown status |
NCT03573271 |
|
|
17 |
Use of 2 Octyl-cyanoacrylate Together With a Self-adhering Mesh for Skin Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study |
Completed |
NCT01658163 |
|
|
18 |
A Prospective, Multi-Center, Evaluator-Blinded Study Evaluating the Safety and Effectiveness of the Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region |
Completed |
NCT04146467 |
|
|
19 |
Feasibility Study: Evaluation Of The Ulthera™ System For Obtaining Lift And Tightening Of The Neck Skin In Patients With A History Of Submentoplasty And Or Rhytidectomy Vs Patients Naïve To Submentoplasty Or Rhytidectomy - A Feasibility Study |
Completed |
NCT01708928 |
|
|
20 |
Randomized-controlled Split-face Treatment of Facial Rhytids and Laxity in Asians Using Long-pulse 1064nm Laser |
Completed |
NCT01971736 |
|
|
21 |
Efficacy and Tolerance Evaluation of an Antiage Aesthetic Treatment for the Middle and Inferior Third of the Face |
Completed |
NCT04239768 |
|
|
22 |
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance |
Completed |
NCT04721600 |
|
|
23 |
Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar Radio Frequency and Pulsed Electromagnetic Field Therapy Technologies for the Treatment of the Mon Pubis, Vaginal Introitus and Labia Skin Laxity |
Completed |
NCT02770287 |
|
|
24 |
TP-1013 Pilot 1: Application of the Apsara Thermal Wand System |
Completed |
NCT00662389 |
Early Phase 1 |
|
25 |
Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin |
Completed |
NCT01708525 |
|
|
26 |
Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity Using a Customized, High-Density and Vectoring Treatment Approach |
Completed |
NCT01708512 |
|
|
27 |
Feasibility Study: Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Laxity/Crepiness and Texture of Abdominal Tissue |
Completed |
NCT01708499 |
|
|
28 |
Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Knees |
Completed |
NCT01708434 |
|
|
29 |
Feasibility Study: Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Neck in Post-Surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ultherapy™ Treatment |
Completed |
NCT01708252 |
|
|
30 |
Elaborated Analysis of Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty on Corneal Nerves, Meibomian Glands, Dry Eye Parameters, and Eyebrow Position |
Completed |
NCT05528016 |
|
|
31 |
Dermal Cryotherapy in Patients Undergoing Abdominoplasty |
Completed |
NCT02763306 |
|
|
32 |
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients |
Completed |
NCT03351335 |
|
|
33 |
Feasibility Study: Comparison Of Advil® Vs. Lortab® For Reducing Discomfort Associated With Ultherapy™ Treatment |
Completed |
NCT01708473 |
|
Advil;Lortab |
34 |
Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening the Buttocks and Thighs |
Completed |
NCT01708460 |
|
|
35 |
Feasibility Study: Evaluation of the Efficacy of a Liposome-encapsulated Lidocaine Topical Anesthetic for Reducing Discomfort Associated With Ultherapy™ Treatment |
Completed |
NCT01708447 |
|
L.M.X.4.® cream |
36 |
Treatment With the Evoke System for Facial and Submental Laxity |
Completed |
NCT04719013 |
|
|
37 |
Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Elbow Tissue - A Feasibility Study |
Completed |
NCT01708382 |
|
|
38 |
Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity |
Completed |
NCT03545412 |
|
|
39 |
Exploratory Evaluation of the Lutronic Genius System for Treatment of the Neck |
Completed |
NCT03534609 |
|
|
40 |
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device |
Completed |
NCT05254210 |
|
|
41 |
A Prospective, Multi-center, Randomized Pilot Study for the Safety and Efficacy of a GEN II Micro-coring Device for the Treatment of Wrinkles and Skin Laxity in the Pre-auricular Area and Mid to Lower Face |
Completed |
NCT03228641 |
|
|
42 |
Face-Q Patient-Report Assisted Subjective and Objective Evaluation of Upper Eye Lid Blepharoplasty Outcomes Using Different Suturing Techniques: A Randomized Observer and Patient-Blinded Pilot Study |
Completed |
NCT04924972 |
|
|
43 |
The Prevalence of Dry Eye Syndrome Among Patients Who Underwent Upper Eyelids Blepharoplasty With and Without Muller Muscle Resection |
Completed |
NCT02376556 |
|
|
44 |
Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences |
Completed |
NCT03599349 |
|
|
45 |
A Prospective, Multi-center, Pilot Study to Evaluate the Efficacy of Micro-Excisional Skin Remodeling With Micro-Coring Device in the Treatment of Wrinkles and Skin Laxity of Face and Neck |
Completed |
NCT03583918 |
|
|
46 |
Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse |
Completed |
NCT02444169 |
|
Incobotulinumtoxin A |
47 |
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers |
Completed |
NCT02416076 |
|
|
48 |
Rollover Study to Evaluate Histological Results of Radiofrequency Device Treatments on the Flanks |
Completed |
NCT04881149 |
|
|
49 |
Evaluation of the Effectiveness and Safety of the Ulthera® DeepSEE® System for Treating Skin Laxity in the Lower Face and Submentum |
Completed |
NCT04795622 |
|
|
50 |
Non-Randomized, Open-label, Blinded Evaluator Study Characterizing Effectiveness of Hybrid Fractional Laser for the Treatment of Off Face Body Skin Quality |
Completed |
NCT03969485 |
|
|
Cochrane evidence based reviews: cutis laxa
|